title: Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
abstract: BACKGROUND
  We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints.
  
  
  METHODS
  From November 1998 to November 2001, 46 patients with pre-treated, advanced ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor marker level (CA 125).
  
  
  RESULTS
  The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two patients were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval 7.9-12.8 months).
  
  
  CONCLUSIONS
  The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight to the reproducibility of results from different centres.
authors.affiliation: Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK. sanjay.sharma@porthosp.nhs.uk
authors.forename: Sanjay
authors.initials: S
authors.lastname: Sharma
authors.forename: Michael H
authors.initials: MH
authors.lastname: Neale
authors.forename: Federica
authors.initials: F
authors.lastname: Di Nicolantonio
authors.forename: Louise A
authors.initials: LA
authors.lastname: Knight
authors.forename: Pauline A
authors.initials: PA
authors.lastname: Whitehouse
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Mercer
authors.forename: Bernard R
authors.initials: BR
authors.lastname: Higgins
authors.forename: Alan
authors.initials: A
authors.lastname: Lamont
authors.forename: Richard
authors.initials: R
authors.lastname: Osborne
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Hindley
authors.forename: Christian M
authors.initials: CM
authors.lastname: Kurbacher
authors.forename: Ian A
authors.initials: IA
authors.lastname: Cree
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D015203:Reproducibility of Results; D016879:Salvage Therapy; D012680:Sensitivity and Specificity